• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Immunotoxicol . A four-week study on the toxicity of repeated intramuscular administration of plant-based BA-CoV2-0301 vaccine against SARS-CoV-2

tetano

Editor, Senior Moderator
J Immunotoxicol


. 2025 Dec;22(1):2504401.
doi: 10.1080/1547691X.2025.2504401. Epub 2025 May 14. A four-week study on the toxicity of repeated intramuscular administration of plant-based BA-CoV2-0301 vaccine against SARS-CoV-2 in Sprague-Dawley rats

Sang-Jin Park[SUP] 1 [/SUP], Seonghyeon Kim[SUP] 1 2 [/SUP], Eun-Young Gu[SUP] 1 [/SUP], Heejin Park[SUP] 1 [/SUP], Wan-Jung Im[SUP] 1 [/SUP], Seung Eui Min[SUP] 1 3 [/SUP], Bo-Hwa Choi[SUP] 4 [/SUP], NamHyung Kim[SUP] 4 [/SUP], Min Seong Jang[SUP] 1 [/SUP], Yoongi Kim[SUP] 1 [/SUP], Kang-Hyun Han[SUP] 1 3 [/SUP], Kyong-Cheol Ko[SUP] 5 [/SUP], Eui-Ju Hong[SUP] 2 [/SUP], Yong-Bum Kim[SUP] 1 [/SUP]



Affiliations
Free article Abstract

In December 2019, the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was identified in Wuhan, China, leading to the global Coronavirus Disease pandemic. The rapid spread of SARS-CoV-2 highlighted the urgent need for effective vaccines. However, the high cost, cold storage requirements, and scalability challenges associated with mRNA vaccines have necessitated alternative vaccine technologies. In the study, the safety of a plant-based vaccine was evaluated. The vaccine, an emulsion of the SARS-CoV-2 S1 antigen and a synthetic TLR4 agonist produced and purified from Nicotiana benthamiana, was administered to Sprague-Dawley rats three times over 4 wk. Mortality, clinical signs, body weight, food consumption, vision, urinalysis, gross findings, organ weight, hematology, serum biochemistry, histopathology, and immunogenicity were evaluated. The results showed that antibodies were efficiently produced and maintained for one month following vaccination with the plant-derived receptor-binding domain (RBD) antigen of COVID-19. Furthermore, the rats showed no toxicological symptoms, with reversible changes at the injection site and minor histological alterations in the spinal cord and bone marrow, typical of vaccine responses. The plant-derived SARS-CoV-2 vaccine appears safe following repeated administration over 4 wk and represents a promising alternative for potential use in human clinical trials and clinical applications.

Keywords: Nicotiana benthamiana; SARS-CoV-2; plant-derived vaccine; preclinical study; toxicity.

 
Back
Top Bottom